4.1. PD-1/PD-L1 blockade Although PD-1/PD-L1 blockade therapies have shown promising results in various types of cancers, the effect of these therapies in PCa remains ambiguous. In a large phase I trial for testing the safety and efficacy of nivolumab (an anti-PD1 antibody) among 296 pat...
Radiotherapy in combination with androgen deprivation therapy (ADT) is a standard treatment option for men with localized and locally advanced prostate cancer. However, emerging clinical evidence suggests that radiotherapy can be incorporated into multimodality therapy regimens beyond ADT, in combinations tha...
Prostate adenocarcinoma (PRAD) persists as the predominant non-cutaneous malignancy diagnosed in males, which is a primary contributor to cancer-related mortality globally. It is reported that the progression of prostate adenocarcinoma is associated with
Last year, Lu et al [175], demonstrated that robust synergistic responses could be achieved in mCPRC mouse models when immune checkpoint blockade (anti-CTLA4 and anti-PD1) was combined with MDSC-targeted therapy (cabozantinib and BEZ235), while the single use of either one of them engendered ...
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient prognosis and therapy resistanc
Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types. However, mCRPC...
Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic defects are major factors that determine the aggressiveness and lethality of PC. The African population is
Prostate cancer (PCa) is the most prevalent genitourinary malignancy in men, with a significant proportion of patients developing biochemical recurrence (BCR) after treatment. The immune microenvironment and metabolic alterations have crucial implication
Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types. However, mCRPC...
Checkpoint Blockade (ICB) to strategies that boost the T cell activity32. In this work, we focus on Prostate Cancer (PCa), one of the leading causes of cancer-associated death in the male population33,34,35. Patients diagnosed with localized PCa are usually monitored for their blood levels ...